SG3 Management’s Acadia Pharmaceuticals ACAD Stock Holding History

SG3 Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-35,500	Closed	-$860K	–	397
2022 Q1	$860K	Sell	35,500 -125,500	-78%	-$3.04M	0.02%	486
2021 Q4	$3.76M	Buy	161,000 +146,000	+973%	+$2.94M	0.08%	229
2021 Q3	$249K	Buy	+15,000	New	+$289K	0.01%	744
2021 Q2	–	Sell	-10,000	Closed	-$258K	–	984
2021 Q1	$258K	Buy	+10,000	New	+$440K	0.01%	919

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SG3 Management's ACAD Position: Q3 2022 in Review

SG3 Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 64,500 shares — an estimated $909K sold.

SG3 Management first reported a position in ACAD in Q1 2019 and held it in 5 quarters. The position peaked at $1.41M in Q1 2022. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

SG3 Management reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
SG3 Management sold 64,500 Acadia Pharmaceuticals shares in Q3 2022, an estimated $909K.
SG3 Management first reported a position in Acadia Pharmaceuticals in Q1 2019 and held it in 5 quarters.
SG3 Management's Acadia Pharmaceuticals position peaked at $1.41M in Q1 2022.
223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on SG3 Management's 13F filing for Q3 2022, filed 14 Nov 2022.